Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 1/20 | 0.54 |
| ▸ | NOS2 | P35228 | 1/20 | 0.51 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.45 |
| ▸ | CHRNG | P07510 | 2/20 | 0.45 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.45 |
| ▸ | CHRND | Q07001 | 2/20 | 0.45 |
| ▸ | HPGDS | O60760 | 3/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | BCL2 | P10415 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.43 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 2/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27670131 | 1.00 | GRIA2 (0.54) | GRIA2NOS2CHRNA1CHRNGCHRNB1 | |
| SCHEMBL22290967 | 0.84 | SLC1A1 (0.57) | FOLH1 | |
| SCHEMBL23646690 | 0.84 | GRIA2 (0.57) | GRIA2NOS2CHRNA1CHRNGCHRNB1 | |
| SCHEMBL28484803 | 0.84 | GRIA2 (0.57) | GRIA2NOS2CHRNA1CHRNGCHRNB1 | |
| SCHEMBL25101016 | 0.84 | GRIA2 (0.54) | GRIA2NOS2CHRNA1CHRNGCHRNB1 | |
| SCHEMBL3130840 | 0.84 | GRIA2 (0.54) | GRIA2NOS2CHRNA1CHRNGCHRNB1 | |
| SCHEMBL11503758 | 0.83 | NOS2 (0.54) | GRIA2NOS2CHRNA1CHRNGCHRNB1 | |
| SCHEMBL11503757 | 0.83 | NOS2 (0.54) | GRIA2NOS2CHRNA1CHRNGCHRNB1 | |
| SCHEMBL31345792 | 0.83 | MME (0.57) | FOLH1ACEMMP2MMP9 | |
| SCHEMBL199980 | 0.83 | MME (0.57) | FOLH1ACEMMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1909853-A2 | IMAGING PROTOCOLS | Spectrum Dynamics LLC (US) | 2008-04-16 | — | — | EP | claimed |
| WO-2008010227-A2 | IMAGING PROTOCOLS | SPECTRUM DYNAMICS LLC (US) | 2008-01-24 | — | — | WO | claimed |
| WO-2007010534-A2 | IMAGING PROTOCOLS | SPECTRUM DYNAMICS LLC (US) | 2007-01-25 | — | — | WO | claimed |
| US-20040258615-A1 | System and method for synthesis of molecular imaging probes including FDG | MOLECULAR TECHNOLOGIES, INC. | 2004-12-23 | — | — | US | claimed |
| US-20180243249-A1 | METHODS OF TREATING PARKINSON'S DISEASE USING VIRAL VECTORS | GENZYME CORPORATION (US) | 2018-08-30 | — | — | US | disclosed |
| EP-2373992-B1 | APPARATUS AND METHOD FOR AUTOMATED QUALITY CONTROL | SIEMENS MEDICAL SOLUTIONS USA INC (US) | 2017-03-29 | — | — | EP | disclosed |
| US-9492415-B2 | Methods of treating Parkinson's disease using viral vectors | GENZYME CORPORATION (US) | 2016-11-15 | — | — | US | disclosed |
| US-20160256534-A1 | METHODS OF TREATING PARKINSON'S DISEASE USING VIRAL VECTORS | GENZYME CORPORATION (US) | 2016-09-08 | — | — | US | disclosed |
| EP-2357178-B1 | Process for the production of L-2-[18F]fluor-phenylalanine and 6-[18F]fluor-L-meta-tyrosine and their alpha-alkylated derivatives from a precursor. | FORSCHUNGSZENTRUM JUELICH GMBH (DE) | 2014-05-07 | — | — | EP | disclosed |
| EP-2691412-A1 | MACROCYCLIC COMPOUND AND METHODS FOR ITS PRODUCTION | Neurovive Pharmaceutical AB (SE) | 2014-02-05 | — | — | EP | disclosed |
| US-20130101510-A1 | METHODS OF TREATING PARKINSON'S DISEASE USING VIRAL VECTORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-04-25 | — | — | US | disclosed |
| US-8309355-B2 | Methods of treating Parkinson's disease using viral vectors | GENZYME CORPORATION (US) | 2012-11-13 | — | — | US | disclosed |
| EP-1621625-A2 | AAV vectors for the manufacture of medicaments for convention enhanced delivery | AVIGEN INCORPORATED (US) | 2006-02-01 | — | — | EP | disclosed |
| EP-1080202-B1 | CONVECTION-ENHANCED DELIVERY OF AAV VECTORS ENCODING AADC | AVIGEN INC (US) | 2006-01-25 | — | — | EP | disclosed |
| WO-2005116224-A2 | TETRACYCLINE-REGULATED ADENO-ASSOCIATED VIRAL (AAV) VECTORS FOR GENE DELIVERY TO THE NERVOUS SYSTEM | CHILDREN'S MEMORIAL HOSPITAL (US) | 2005-12-08 | — | — | WO | disclosed |
| US-6953575-B2 | Methods of treating central nervous system disorders using viral vectors | AVIGEN, INC. (US) | 2005-10-11 | — | — | US | disclosed |
| US-20050180955-A1 | Methods of treating parkinson's disease using viral vectors | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-08-18 | — | — | US | disclosed |
| WO-2004105787-A1 | METHODS OF USING COMBINATIONS OF EGF-2 AND EGF-20 TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS | THE UNIVERSITY OF KYOTO (US) | 2004-12-09 | — | — | WO | disclosed |
| US-20020141980-A1 | Convection-enhanced delivery of AAV vectors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2002-10-03 | — | — | US | disclosed |
| US-6309634-B1 | DELIVERING VIRAL VECTORS TO THE CNS ARE PROVIDED. | AVIGEN, INC. | 2001-10-30 | — | — | US | disclosed |